肿瘤标志物在肺结节良恶性诊断中的现状及进展

Current Status and Progress of Tumor Markers in Diagnosis of Benign and Malignant Pulmonary Nodules

随着影像学技术的发展,肺结节的检出率逐年升高。目前,临床判断肺结节良恶性的方法较多,其中血液肿瘤标志物对无症状肿瘤的敏感性和特异性均较高,可作为早期判断肺结节性质的理想方法之一,故成为目前的研究热点。除血液肿瘤标志物广泛用于临床肺恶性肿瘤检测外,其他血清肿瘤标志物(如糖类抗原125、铁蛋白、血管生成标志物等)亦可用于肺结节性质的早期评估,甚至可评估不同病理分类恶性肺结节的治疗效果及预后,并可能有助于提高肺结节早期诊断的敏感性及特异性。

With the development of imaging technology,the detection rate of pulmonary nodules has been increasing year by year.At present,there are many clinical methods to judge the benign and malignant pulmonary nodules.Among them,the sensitivity and specificity of blood tumor markers to asymptomatic tumors are high,which can be used as one of the ideal methods to early judge the nature of pulmonary nodules,so it has become a research hotspot.In addition to blood tumor markers widely used in the detection of malignant pulmonary tumors in clinical,other blood markers(such as carbohydrate antigen 125,ferritin,angiogenesis markers,etc.) can also be used for early assessment of the nature of pulmonary nodules,and can even evaluate the therapeutic effect and prognosis of malignant pulmonary nodules with different pathological classifications,and may help to improve the sensitivity and specificity of early diagnosis of pulmonary nodules.